Design, construction and evaluation of multi-epitope antigens for diagnosis of Lyme disease
More details
Hide details
Laboratory of Biomedical Microbiology and Immunology, Department of Microbiology and Immunology, University of Veterinary Medicine and Pharmacy, 041 81 Kosice, Slovakia
Institute of Neuroimmunology, Slovak Academy of Sciences, 845 10 Bratislava, Slovakia
Corresponding author
Lucia Borszekova Pulzova   

University of veterinary medicine and pharmacy in Kosice, Komenskeho 73, 040 81 Kosice, Slovak Republic
Ann Agric Environ Med. 2017;24(4):696-701
Introduction and objective. Lyme disease (LD) is the most common vector-borne disease in the temperate zone of the Northern Hemisphere. Diagnosis of LD is mainly based on clinical symptoms supported with serology (detection of anti-Borrelia antibodies) and is often misdiagnosed in areas of endemicity.

Material and methods:
In this study, the chimeric proteins (A/C-2, A/C-4 and A/C-7.1) consisting of B-cell epitopes of outer surface proteins OspA and OspC from Borrelia genospecies prevalent in Eastern Slovakia, were designed, over-expressed in E. coli, and used to detect specific anti-Borrelia antibodies in serologically characterized sera from patients with Lyme-like symptoms to evaluate their diagnostic potential.

Results showed that chimeras vary in their immuno-reactivity when tested with human sera. Compared with the results obtained from a two-tier test, the application of recombinant multi-epitope chimeric proteins as diagnosis antigens, produced fair agreement in the case of A/C-2 (0.20<κ<0.40) and good agreement (0.60<κ<0.80) when A/C-7.1 was used as capture antigen. Chimera A/C-4 were excluded from further study due to loss of reactivity with OspA-specific antibodies.

The combination of specific B-cell epitopes from OspA and OspC proteins may improve the diagnostic accuracy of serologic assays, but further studies are required to address this hypothesis.

Wilske B, Fingerle V, Schulte-Spechtel U. Microbiological and serological diagnosis of Lyme borreliosis. FEMS Immunol Med Microbiol. 2007; 49(1): 13–21.
Steere AC, McHugh G, Damle N, Sikand VK. Prospective study of serologic tests for lyme disease. Clin Infect Dis. 2008; 47(2): 188–95.
Aguero-Rosenfeld ME, Wormser GP. Lyme disease: diagnostic issues and controversies. Expert Rev Mol Diagn. 2015; 15(1): 1–4.
Reed KD. Laboratory testing for Lyme disease: possibilities and practicalities. J Clin Microbiol. 2002; 40(2): 319–24.
Cheung CS, Anderson KW, Benitez KY, Soloski MJ, Aucott JN, Phinney KW et al. Quantification of Borrelia burgdorferi Membrane Proteins in Human Serum: A New Concept for Detection of Bacterial Infection. Anal Chem. 2015; 87(22): 11383–8.
Hsieh YF, Liu HW, Hsu TC, Wei JC, Shih CM, Krause PJ et al. Serum reactivity against Borrelia burgdorferi OspA in patients with rheumatoid arthritis. Clin Vaccine Immunol. 2007; 14(11): 1437–41.
Ding W, Huang X, Yang X, Dunn JJ, Luft BJ, Koide S et al. Structural identification of a key protective B-cell epitope in Lyme disease antigen OspA. J Mol Biol. 2000; 302(5): 1153–64.
Aguero-Rosenfeld ME, Nowakowski J, Bittker S, Cooper D, Nadelman RB, Wormser GP. Evolution of the serologic response to Borrelia burgdorferi in treated patients with culture-confirmed erythema migrans. J Clin Microbiol. 1996; 34(1): 1–9.
Pulzova L, Flachbartova Z, Bencurova E, Potocnakova L, Comor L, Schreterova E et al. Identification of B-cell epitopes of Borrelia burgdorferi outer surface protein C by screening a phage-displayed gene fragment library. Microbiol Immunol. 2016; 60(10): 669–677.
Tilly K, Rosa PA, Stewart PE. Biology of infection with Borrelia burgdorferi. Infect Dis Clin North Am. 2008; 22(2): 217–34, v.
Robertson J, Guy E, Andrews N, Wilske B, Anda P, Granstrom M et al. A European multicenter study of immunoblotting in serodiagnosis of lyme borreliosis. J Clin Microbiol. 2000; 38(6): 2097–102.
Mlynarcik P, Pulzova L, Bencurova E, Kovac A, Dominguez MA, Hresko S et al. Deciphering the interface between a CD40 receptor and borrelial ligand OspA. Microbiol Res. 2015; 170: 51–60.
Pulzova L, Kovac A, Mucha R, Mlynarcik P, Bencurova E, Madar M et al. OspA-CD40 dyad: ligand-receptor interaction in the translocation of neuroinvasive Borrelia across the blood-brain barrier. Sci Rep. 2011; 1: 86.
Alcaro MC, Peroni E, Rovero P, Papini AM. Synthetic peptides in the diagnosis of HIV infection. Curr Protein Pept Sci. 2003; 4(4): 285–90.
Maksimov P, Zerweck J, Maksimov A, Hotop A, Gross U, Pleyer U et al. Peptide microarray analysis of in silico-predicted epitopes for serological diagnosis of Toxoplasma gondii infection in humans. Clinical and Vaccine Immunology. 2012; 19(6): 865–74.
Yang XF, Pal U, Alani SM, Fikrig E, Norgard MV. Essential role for OspA/B in the life cycle of the Lyme disease spirochete. J Exp Med. 2004; 199(5): 641–8.
Wagner B, Freer H, Rollins A, Garcia-Tapia D, Erb HN, Earnhart C et al. Antibodies to Borrelia burgdorferi OspA, OspC, OspF, and C6 antigens as markers for early and late infection in dogs. Clin Vaccine Immunol. 2012; 19(4): 527–35.
Schutzer SE, Coyle PK, Dunn JJ, Luft BJ, Brunner M. Early and specific antibody response to OspA in Lyme Disease. J Clin Invest. 1994; 94(1): 454–7.
Gomes-Solecki MJ, Dunn JJ, Luft BJ, Castillo J, Dykhuizen DE, Yang X et al. Recombinant chimeric Borrelia proteins for diagnosis of Lyme disease. J Clin Microbiol. 2000; 38(7): 2530–5.
Bakken LL, Callister SM, Wand PJ, Schell RF. Interlaboratory comparison of test results for detection of Lyme disease by 516 participants in the Wisconsin State Laboratory of Hygiene/College of American Pathologists Proficiency Testing Program . J Clin Microbiol. 1997; 35(3): 537–43.
Ang CW, Notermans DW, Hommes M, Simoons-Smit AM, Herremans T. Large differences between test strategies for the detection of anti-Borrelia antibodies are revealed by comparing eight ELISAs and five immunoblots. Eur J Clin Microbiol Infect Dis. 2011; 30(8): 1027–32.
Journals System - logo
Scroll to top